美國居民不適用 XM 服務。
T
T

ThermoFisher

技術摘要

指標價值趨勢
指標價值趨勢
指標價值趨勢
指標S3S2S1PR1R2R3

財經新聞

U.S. CarMax, Eli Lilly, MicroStrategy

U.S. RESEARCH ROUNDUP-CarMax, Eli Lilly, MicroStrategy June 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CarMax, Eli Lilly and MicroStrategy, on Monday. HIGHLIGHTS * CarMax Inc KMX.N : RBC raises target price to $75 from $73 * Eli Lilly LLY.N : Jefferies raises target price to $1,015 from $994 * MicroStrategy Inc MSTR.O : Canaccord Genuity cuts target price to $1,826 from $2,047 * Sharecare Inc SHCR.O : Canacco
A
A
B
D
G
M
N
V
E
F
T
E
P
R
T
C
C
I

Sarepta surges on FDA's expanded use nod for company's Duchenne gene therapy

BUZZ-Sarepta surges on FDA's expanded use nod for company's Duchenne gene therapy ** Shares of Sarepta Therapeutics SRPT.O surged about 33% to a more than three-year high in early trade ** At current levels, nearly $4 bln was set to be added to company's market value ** Late on Thursday, U.S. FDA granted traditional approval for company's gene therapy, Elevidys, for patients with inherited progressive muscle-wasting disorder ** Agency's nod allows use in kids aged four-year and above who can wal
T

Sarepta surges as investors cheer expanded use of gene therapy

UPDATE 2-Sarepta surges as investors cheer expanded use of gene therapy Adds background on FDA decision in paragraph 4, CEO quote in paragraphs 8 & 9, analyst quote in paragraph 12 & 13 By Mariam Sunny and Bhanvi Satija June 21 (Reuters) - Sarepta Therapeutics SRPT.O shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for Duchenne muscular dystrophy (DMD).
N
P
T

Thermo Fisher Scientific Expands Clinical Research Laboratory In Wisconsin

BRIEF-Thermo Fisher Scientific Expands Clinical Research Laboratory In Wisconsin June 18 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC EXPANDS CLINICAL RESEARCH LABORATORY IN WISCONSIN Source text for Eikon: ID:nBw21nSLsa Further company coverage: TMO.N
T

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions To Comply With IVDR Regulation

BRIEF-Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions To Comply With IVDR Regulation May 31 (Reuters) - Thermo Fisher Scientific Inc TMO.N : THERMO FISHER SCIENTIFIC UPDATES CHROMOSOMAL MICROARRAY ANALYSIS SOLUTIONS TO COMPLY WITH IVDR REGULATION THERMO FISHER SCIENTIFIC INC: APPLIED BIOSYSTEMS™ CYTOSCAN™ DX AND CHROM
T

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明